ENCORSTAT

Welcome to the Brand page for “ENCORSTAT”, which is offered here for In the statement, page 2, column 1, line 12,12-9-2009 should be deleted, and 12-3-2009 should be inserted.;gene therapy products, genetically engineered tissues for transplant purposes and gene delivery pharmaceuticals; vaccines, enzymes and enzyme preparations, anti-apoptopic and angiostatic / angiogenic molecules, all for medical purposes in connection with the treatment of diseases of the eye; nucleic acid sequences and chemical reagents for medical purposes in connection with the treatment of diseases of the eye, retroviral vectors and retroviral vector manufacturing preparations; pharmaceutical and biochemical preparations for the treatment of diseases of the eye and usher's disease; biochemical preparations for medical purposes, gene based therapeutics for the treatment of a juvenile degenerative retinal disease; pre-filled vials containing gene therapy pharmaceutical preparations in connection with the treatment of diseases of the eye;encore stat;color is not claimed as a feature of the mark.;enzymes for scientific and research purposes in connection with treatment of the eye; chemicals for use in industry and science, chemicals for in-vitro use and analysis in laboratories in connection with treatment for the eye; micro-organisms, cell cultures, plasmids and cultures of micro-organisms, deoxyribonucleic acid sequences, nucleic acid sequences and chemical reagents for other than medical and veterinary purposes, cloning vehicles and vectors and recombinant deoxyribonucleic acid variations thereof, all for in-vitro and in-vivo use in laboratory or medical research in connection with treatment for the eye; chemical reagents for use in medical science;medical instruments and apparatus for the administration of antibody-based therapy, gene therapy and prophylaxis preparations and substances in connection with the treatment of diseases of the eye; syringes and injectors for medical purposes in connection with the treatment of diseases of the eye;scientific and medical research and development in connection with the treatment of diseases of the eye; genetic engineering services, biotechnology services, research and development of new products for others in the field of biotechnology in connection with the treatment of diseases of the eye; advisory services relating to research and development of gene therapy products all in connection with the treatment of diseases of the eye and specifically excluding analysis services;.

Its status is currently believed to be active. Its class is unavailable. “ENCORSTAT” is believed to be currently owned by “Oxford BioMedica plc”.